Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2025 | $60.00 | Overweight | Barclays |
| 6/28/2024 | $36.00 | Neutral → Buy | Guggenheim |
| 6/3/2024 | $32.00 | Buy | Jefferies |
| 4/24/2024 | $28.00 | Buy | Craig Hallum |
| 12/14/2023 | Neutral | Guggenheim | |
| 12/13/2023 | Peer Perform | Wolfe Research | |
| 11/13/2023 | $27.00 | Mkt Perform → Outperform | Raymond James |
| 9/28/2023 | $34.00 | Outperform | Bernstein |
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G - Guardant Health, Inc. (0001576280) (Subject)
SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)
Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Time Leerink Partners Global Health Conference in Miami, FL Fireside chat on Tuesday, March 11th at 4:20 p.m. Eastern Time Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL Fireside chat on Wednesday, March 12t
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the "Exchange Agreements") with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the "2027 Notes"), pursuant to which the Company will issue $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (the "New Notes") in exchange for the retirement of approximately $659.3 million principal amount of 2027 Notes (the "Transactions"). The initial conversion rate of the New Notes will be 16.0716 shares of Guardant Health's common stock (the "common stock"), per $1,000 principal
For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C
For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap
For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry
10-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
8-K - Guardant Health, Inc. (0001576280) (Filer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
Barclays initiated coverage of Guardant Health with a rating of Overweight and set a new price target of $60.00
Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00
Jefferies resumed coverage of Guardant Health with a rating of Buy and set a new price target of $32.00
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
4 - Guardant Health, Inc. (0001576280) (Issuer)
Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer.
Revenue growth of 34% driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds Shield received favorable Medicare pricing of $920 Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Recorded revenue of $191.5 million for the third quarter of 2024, an increase of 34% over the third quarter of 2023 Reported 53,100 clinical tests (excluding Shield) and 10,500 biopharma tests in the third quarter of 2024, representing increases of 21% and 40%, respectively, over the third quarter of 2023 Achieved Guardant360 ASP of over $3,000 Rai
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look
Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the addition of Terilyn Juarez Monroe as the company's chief people officer, effective immediately. In the newly-created role, Monroe will lead the human resources function, including people operations; cultural and organizational transformation; talent acquisition; and diversity and inclusion initiatives. Amelia Merrill, who previously served as senior vice president of people, is transitioning to an advisory role with the company. "Terilyn brings deep expertise in leading, transforming, and scaling the human resources function at rapidly growing companies, and we welcome her leadership as we pursu